Noncoding RNAs regulate NF-κB signaling to modulate blood vessel inflammation. 2014

Henry S Cheng, and Makon-Sébastien Njock, and Nadiya Khyzha, and Lan T Dang, and Jason E Fish
Toronto General Research Institute, University Health Network Toronto, ON, Canada ; Department of Laboratory Medicine and Pathobiology, University of Toronto Toronto, ON, Canada ; Heart and Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research Toronto, ON, Canada.

Cardiovascular diseases such as atherosclerosis are one of the leading causes of morbidity and mortality worldwide. The clinical manifestations of atherosclerosis, which include heart attack and stroke, occur several decades after initiation of the disease and become more severe with age. Inflammation of blood vessels plays a prominent role in atherogenesis. Activation of the endothelium by inflammatory mediators leads to the recruitment of circulating inflammatory cells, which drives atherosclerotic plaque formation and progression. Inflammatory signaling within the endothelium is driven predominantly by the pro-inflammatory transcription factor, NF-κB. Interestingly, activation of NF-κB is enhanced during the normal aging process and this may contribute to the development of cardiovascular disease. Importantly, studies utilizing mouse models of vascular inflammation and atherosclerosis are uncovering a network of noncoding RNAs, particularly microRNAs, which impinge on the NF-κB signaling pathway. Here we summarize the literature regarding the control of vascular inflammation by microRNAs, and provide insight into how these microRNA-based pathways might be harnessed for therapeutic treatment of disease. We also discuss emerging areas of endothelial cell biology, including the involvement of long noncoding RNAs and circulating microRNAs in the control of vascular inflammation.

UI MeSH Term Description Entries

Related Publications

Henry S Cheng, and Makon-Sébastien Njock, and Nadiya Khyzha, and Lan T Dang, and Jason E Fish
January 2016, Advances in experimental medicine and biology,
Henry S Cheng, and Makon-Sébastien Njock, and Nadiya Khyzha, and Lan T Dang, and Jason E Fish
October 2019, Molecular and cellular biology,
Henry S Cheng, and Makon-Sébastien Njock, and Nadiya Khyzha, and Lan T Dang, and Jason E Fish
October 2022, Molecular neurobiology,
Henry S Cheng, and Makon-Sébastien Njock, and Nadiya Khyzha, and Lan T Dang, and Jason E Fish
January 2022, Progress in molecular biology and translational science,
Henry S Cheng, and Makon-Sébastien Njock, and Nadiya Khyzha, and Lan T Dang, and Jason E Fish
January 2017, Signal transduction and targeted therapy,
Henry S Cheng, and Makon-Sébastien Njock, and Nadiya Khyzha, and Lan T Dang, and Jason E Fish
November 2022, Experimental and therapeutic medicine,
Henry S Cheng, and Makon-Sébastien Njock, and Nadiya Khyzha, and Lan T Dang, and Jason E Fish
August 2019, International immunopharmacology,
Henry S Cheng, and Makon-Sébastien Njock, and Nadiya Khyzha, and Lan T Dang, and Jason E Fish
April 2022, Cell reports,
Henry S Cheng, and Makon-Sébastien Njock, and Nadiya Khyzha, and Lan T Dang, and Jason E Fish
December 2021, MedComm,
Henry S Cheng, and Makon-Sébastien Njock, and Nadiya Khyzha, and Lan T Dang, and Jason E Fish
February 2020, Experimental and molecular pathology,
Copied contents to your clipboard!